Targeting the embryonic gene Cripto-1 in cancer and beyond

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 12, 2010, Pages 1739-1749

  Bianco, Caterina ^a   Salomon, David S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer vaccines; Cripto 1; degenerative muscle diseases; humanized mAbs; neurodegenerative diseases

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CARBOPLATIN; CELL MEMBRANE PROTEIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; EPIRUBICIN; FLUOROURACIL; GLUCOSE REGULATED PROTEIN 78; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A27.F6.1; MONOCLONAL ANTIBODY A8; MONOCLONAL ANTIBODY A8.G3.5; MONOCLONAL ANTIBODY B3.F6.1; MONOCLONAL ANTIBODY B3.F6.1 MAYTANSINOL CONJUGATE; MONOCLONAL ANTIBODY C13; MONOCLONAL ANTIBODY C4; MONOCLONAL ANTIBODY CH2 DELETED CHIMERIC B3.F6.1; MONOCLONAL ANTIBODY H3.1; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY N20; PROTEIN CRIPTO1; TRIPEPTIDE; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST TUMOR; CLINICAL TRIAL; COLON CANCER; CRIPTO 1 GENE; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; HUMAN; NONHUMAN; PARKINSON DISEASE; PATENT; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATOR GENE; REVIEW; SOLID TUMOR; TERATOMA; TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PATENTS AS TOPIC;

EID: 78649251072     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.530659     Document Type: Review

References (86)

1. Bianco C, Rangel MC, Castro NP, et al. Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol 2010;177:532-40
2. De Castro NP, Rangel MC, Nagaoka T, et al. Cripto-1: an embryonic gene that promotes tumorigenesis. Future Oncol 2010;6:1127-42
3. Colas JF, Schoenwolf GC. Subtractive hybridization identifies chick-cripto, a novel EGF-CFC ortholog expressed during gastrulation, neurulation and early cardiogenesis. Gene 2000;255:205-17
4. Minchiotti G, Manco G, Parisi S, et al. Structure-function analysis of the EGF-CFC family member Cripto identifies residues essential for nodal signalling. Development 2001;128:4501-10
5. Watanabe K, Bianco C, Strizzi L, et al. Growth factor induction of Cripto-1 shedding by GPI-phospholipase D and enhancement of endothelial cell migration. J Biol Chem 2007;282:31643-55
6. Watanabe K, Hamada S, Bianco C, et al. Requirement of glycosylphosphatidylinositol anchor of Cripto-1 for 'trans' activity as a nodal co-receptor. J Biol Chem 2007;289:35772-86
7. Minchiotti G, Parisi S, Liguori G, et al. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development. Mech Dev 2000;90:133-42
8. Schiffer SG, Foley S, Kaffashan A, et al. Fucosylation of Cripto is required for its ability to facilitate nodal signaling. J Biol Chem 2001;276:37769-78
9. Shi S, Ge C, Luo Y, et al. The threonine that carries fucose, but not fucose, is required for Cripto to facilitate nodal signaling. J Biol Chem 2007;282:20133-41
10. Rabbani SA, Mazar AP, Bernier SM, et al. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 1992;267:14151-6
11. Rampal R, Luther KB, Haltiwanger RS. Notch signaling in normal and disease States: possible therapies related to glycosylation. Curr Mol Med 2007;7:427-45
12. Bianco C, Mysliwiec M, Watanabe K, et al. Activation of a Nodal-independent signaling pathway by Cripto-1 mutants with impaired activation of a Nodal-dependent signaling pathway. FEBS Lett 2008;582:3997-4002
13. Bianco C, Strizzi L, Mancino M, et al. Regulation of Cripto-1 signaling and biological activity by caveolin-1 in mammary epithelial cells. Am J Pathol 2008;172:345-57
14. Bianco C, Strizzi L, Normanno N, et al. Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol 2005;67:85-133
15. Strizzi L, Bianco C, Normanno N, Salomon D. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene 2005;24:5731-41
16. Reissmann E, Jornvall H, Blokzijl A, et al. The orphan receptor ALK7 and the activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. Genes Dev 2001;15:2010-22
17. Gray PC, Harrison CA, Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci USA 2003;100:5193-8
18. Gray PC, Shani G, Aung K, et al. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling. Mol Cell Biol 2006;26:9268-78
19. Adkins HB, Bianco C, Schiffer SG, et al. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest 2003;112:575-87
20. Shani G, Fischer WH, Justice NJ, et al. GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Mol Cell Biol 2008;28:666-77
21. Bianco C, Strizzi L, Rehman A, et al. A Nodal-and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res 2003;63:1192-7
22. Bianco C, Adkins HB, Wechselberger C, et al. Cripto-1 activates nodal-and ALK4-dependent and-independent signaling pathways in mammary epithelial Cells. Mol Cell Biol 2002;22:2586-97
23. Watanabe K, Nagaoka T, Lee JM, et al. Enhancement of Notch receptor maturation and signaling sensitivity by Cripto-1. J Cell Biol 2009;187:343-53
24. Hamada S, Watanabe K, Hirota M, et al. beta-Catenin/TCF/LEF regulate expression of the short form human Cripto-1. Biochem Biophys Res Commun 2007;355:240-4
25. Morkel M, Huelsken J, Wakamiya M, et al. Beta-catenin regulates Cripto-and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development 2003;130:6283-94
26. Ciardiello F, Dono R, Kim N, et al. Expression of Cripto, a novel gene of the epidermal growth factor gene family, leads to in vitro transformation of a normal mouse mammary epithelial cell line. Cancer Res 1991;51:1051-4
27. Niemeyer CC, Persico MG, Adamson ED. Cripto: roles in mammary cell growth, survival, differentiation and transformation. Cell Death Differ 1998;5:440-9
28. Brandt R, Normanno N, Gullick WJ, et al. Identification and biological characterization of an epidermal growth factor-related protein: Cripto-1. J Biol Chem 1994;269:17320-8
29. Wechselberger C, Ebert AD, Bianco C, et al. Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. Exp Cell Res 2001;266:95-105
30. Ebert AD, Wechselberger C, Nees M, et al. Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells. Exp Cell Res 2000;257:223-9
31. Normanno N, De Luca A, Bianco C, et al. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol 2004;198:31-9
32. Strizzi L, Bianco C, Normanno N, et al. Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. J Cell Physiol 2004;201:266-76
33. Bianco C, Strizzi L, Ebert A, et al. Role of human Cripto-1 in tumor angiogenesis. J Natl Cancer Inst 2005;97:132-41
34. Bianco C, Cotten C, Lonardo E, et al. Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. Am J Pathol 2009;175:2146-58
35. Wechselberger C, Strizzi L, Kenney N, et al. Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. Oncogene 2005;24:4094-105
36. Sun Y, Strizzi L, Raafat A, et al. Overexpression of human Cripto-1 in transgenic mice delays mammary gland development and differentiation and induces mammary tumorigenesis. Am J Pathol 2005;167:585-97
37. Miyoshi K, Shillingford JM, Le Provost F, et al. Activation of beta-catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci USA 2002;99:219-24
38. Miyoshi K, Rosner A, Nozawa M, et al. Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene 2002;21:5548-56
39. Kuniyasu H, Yasui W, Akama Y, et al. Expression of Cripto in human gastric carcinomas: an association with tumor stage and prognosis. J Exp Clin Cancer Res 1994;13:151-7
40. Saeki T, Stromberg K, Qi CF, et al. Differential immunohistochemical detection of amphiregulin and Cripto in human normal colon and colorectal tumors. Cancer Res 1992;52:3467-73
41. Saeki T, Salomon DS, Johnson GR, et al. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 1995;25:240-9
42. Panico L, D'Antonio A, Salvatore G, et al. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 1996;65:51-6
43. Haruma K, Ito M, Kohmoto K, et al. Expression of cell cycle regulators and growth factor/receptor systems in gastric carcinoma in young adults: association with Helicobacter pylori infection. Int J Mol Med 2000;5:185-90
44. De Angelis E, Grassi M, Gullick WJ, et al. Expression of Cripto and amphiregulin in colon mucosa from high risk colon cancer families. Int J Oncol 1999;14:437-40
45. Miyoshi N, Ishii H, Mimori K, et al. TDGF1 is a novel predictive marker for metachronous metastasis of colorectal cancer. Int J Oncol 2010;36:563-8
46. Gong YP, Yarrow PM, Carmalt HL, et al. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Eur J Surg Oncol 2007;33:438-43
47. Bianco C, Strizzi L, Mancino M, et al. Identification of Cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res 2006;12:5158-64
48. Normanno N, Bianco C, Damiano V, et al. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Clin Cancer Res 1996;2:601-9
49. Hu XF, Xing PX. Cripto as a target for cancer immunotherapy. Expert Opin Ther Targets 2005;9:383-94
50. Ciardiello F, Tortora G, Bianco C, et al. Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene 1994;9:291-8
51. De Luca A, Casamassimi A, Selvam MP, et al. EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. Int J Cancer 1999;80:589-94
52. De Luca A, Arra C, D'Antonio A, et al. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene 2000;19:5863-71
53. Casamassimi A, De Luca A, Agrawal S, et al. EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. Ann Oncol 2000;11:319-25
54. Normanno N, De Luca A, Maiello MR, et al. CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. Int J Oncol 2004;25:1013-20
55. Normanno N, Tortora G, De Luca A, et al. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Oncol Rep 1999;6:1105-9
56. De Luca A, Selvam MP, Sandomenico C, et al. Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. Int J Cancer 1997;73:277-82
57. Deckert PM. Current constructs and targets in clinical development for antibody-based cancer therapy. Curr Drug Targets 2009;10(2):158-75
58. Biogen-Idec. Cripto binding molecules. US0008906; 2010
59. Almagro JC, Fransson J. Humanization of antibodies. Front Biosci 2008;13:1619-33
60. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107
61. Xing PX, Hu XF, Pietersz GA, et al. Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res 2004;64:4018-23
62. McKenzie IFC, Xing PX, Hu XF. Antibodies against cancer. US0119514; 2010
63. Hu XF, Li J, Yang E, et al. Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways. Br J Cancer 2007;96:918-27
64. Gray PC, Shani G, Kelber JA, Vale W. Compositions and methods for the inhibition of Cipto/GRP78 complex formation and signaling. US0135904; 2010
65. Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 2005;35:373-81
66. Davidson DJ, Haskell C, Majest S, et al. Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res 2005;65:4663-72
67. Kelber JA, Panopoulos AD, Shani G, et al. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 2009;28:2324-36
68. Bianco C, Salomon DS. Human Cripto-1 as a target for a cancer vaccine: WO2008040759. Expert Opin Ther Pat 2009;19:141-4
69. Pharmexa. Methods of down-regulation of Cripto. WO2008040759; 2008
70. Glaxosmithkline. Vaccines. US2008249013; 2008
71. Parisi S, D'Andrea D, Lago CT, et al. Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells. J Cell Biol 2003;163:303-14
72. Parish CL, Parisi S, Persico MG, et al. Cripto as a target for improving embryonic stem cell-based therapy in Parkinson's disease. Stem Cells 2005;23:471-6
73. Sonntag KC, Simantov R, Bjorklund L, et al. Context-dependent neuronal differentiation and germ layer induction of Smad4-/-and Cripto-/-embryonic stem cells. Mol Cell Neurosci 2005;28:417-29
74. Winkler C, Kirik D, Bjorklund A. Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci 2005;28:86-92
75. Kriks S, Studer L. Protocols for generating ES cell-derived dopamine neurons. Adv Exp Med Biol 2009;651:101-11
76. Lonardo E, Parish CL, Ponticelli S, et al. A small synthetic Cripto blocking Peptide improves neural induction, dopaminergic differentiation, and functional integration of mouse embryonic stem cells in a rat model of Parkinson's disease. Stem Cells 2010;28:1326-37
77. Stephens EB, Jackson M, Cui L, et al. Early dysregulation of Cripto-1 and immunomodulatory genes in the cerebral cortex in a macaque model of neuroAIDS. Neurosci Lett 2006;410:94-9
78. Salomon DS, Berman N. Use of Cripto-1 as a biomarker for neurodegenerative disease and method to inhibit progression thereof. US2007122813; 2007
79. Tedesco FS, Dellavalle A, Diaz-Manera J, et al. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 2010;120:11-19
80. Minchiotti G, Carmeliet P. Means and methods for the stimulation of skeletal muscle regeneration. WO2008028888; 2008
81. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-15
82. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8
83. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401
84. Watanabe K, Meyer MJ, Strizzi L, et al. Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells 2010;28:1303-14
85. Cocciadiferro L, Miceli V, Kang KS, et al. Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines. Ann NY Acad Sci 2009;1155:257-62
86. Strizzi L, Abbott DE, Salomon DS, Hendrix MJ. Potential for Cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle 2008;7:1931-5